Representatives Mike Honda, Hank Johnson, and Judy Chu are asking all
House Representatives to sign an important letter supporting a doubling in
funding for hepatitis B and C programs in the Fiscal Year 2016 appropriations
bill (see text of letter below). This is the same increase in funding that
President Obama recommends in his proposed budget, which was released last month.
The deadline for Representatives to sign the letter is end of day, March
19, 2015.

This is an extraordinary opportunity to ask our House Representatives
for leadership in the fight against the hepatitis B and C epidemics. The more
signatures on this letter, the better chance of securing badly needed funding
to expand testing, linkage to care, surveillance, and other vital services.

Please take a few minutes before March 19th to call your House
Representative’s office in Washington, DC and ask/him to sign this letter.

How you can help:

You can reach your Representative through the Congressional Switchboard
at (202)
224-3121.

Ask to be connected to your Representative. Once you are connected to
the office, ask to speak to the staff person who handles health care issues.
Whether you speak to that person live or leave a voicemail, tell them (1) your
name, (2) where you live and that you are a constituent, (3) that you would
like the Representative to sign the “Dear Colleague” letter from
Representatives Honda, Johnson, and Chu supporting increased funding for viral
hepatitis and (4) a brief message why this issue is important to you. Tell them
they can sign the letter by contacting Helen Beaudreau in Representative Honda’s
office or Scott Goldstein in Representative Johnson’s office.

Text of “Dear Colleague” letter:

The
Honorable Tom Cole
Chairman
Subcommittee on Labor, Health and Human Services
United States House
Washington, D.C., 20515

The Honorable Rosa DeLauro
Ranking Member
Subcommittee on Labor, Health and Human Services
United States House
Washington, D.C., 20515

Dear Chairman Cole and Ranking Member DeLauro:

As you begin deliberations on the Fiscal Year 2016 Labor, Health and
Human Services, Education, and Related Agencies Appropriations bill, we
respectfully request that you allocate $62.8 million for the Division of Viral
Hepatitis (DVH) at the Centers for Disease Control and Prevention (CDC),
consistent with the President’s FY2016 budget request and an increase of $31.5
million over the FY2015 level.

The CDC’s 2010 professional judgment (PJ) budget recommended $90.8
million annually from FY2011-FY2013, $170.3 million annually from
FY2014-FY2017, and $306.3 million annually from FY2018-FY2020 in order for DVH
to comprehensively address the viral hepatitis epidemics. While past increases
have been helpful, these have only been small steps toward building a more
comprehensive response to viral hepatitis. Our recommendation of $62.8 million
is in line with the needs determined by the PJ and the goals of the Viral
Hepatitis Action Plan, but pales in comparison to the CDC’s PJ. These increased
funds would be used to:

Expand
adoption of CDC/United States Preventive Services Task Force (USPSTF)
recommendations for hepatitis B and hepatitis C testing and linkage to
care by health systems and providers to prevent disease and premature
death;

Develop
monitoring systems and prevention strategies to stop the emerging
hepatitis C epidemic among young persons and others at risk;

Strengthen
state and local capacity to detect new infections, coordinate prevention
activities, provide feedback to providers for quality improvement, and
track progress toward prevention goals.

The need to enhance and expand these prevention efforts is growing more
urgent. The hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading
causes of liver cancer – one of the most lethal, expensive and fastest growing
cancers in America. As many as 5.3 million people in the U.S. are living with
HBV and/or HCV and 65-75% of them are undiagnosed. Approximately 175,000
veterans are living with HCV, and at least 30,000 of them have liver cirrhosis
(scarring of the liver); yet as many as 40,000 veterans may be infected with
HCV and not know it. Without an adequate comprehensive surveillance system,
these estimates are only the tip of the iceberg. There are at least 18,000
deaths annually attributed to hepatitis-related liver disease or liver cancer,
and hepatitis is the leading non-AIDS cause of death in people living with HIV.
In fact, nearly 25 percent of HIV-positive persons are also infected with HCV
and nearly 10 percent with HBV.

These epidemics are particularly alarming because of the rising rates of
new infections and high rates of chronic infection among disproportionately
impacted racial and ethnic populations. They present a dramatic public health
inequity. For example, Asian Americans comprise more than half of the known
hepatitis B population in the United States and, consequently, maintain the
highest rate of liver cancer among all ethnic groups. American Indian/Alaska
Native communities have the highest incidence rates of HCV among all races and
ethnicities. HCV is twice as prevalent among African Americans as among
Caucasians. Additionally, African American and Latino patients are less likely
to be tested for HCV in the presence of a known risk factor, less likely to be
referred to treatment for subspecialty care and treatment, and less likely to
receive antiviral treatment. Recent alarming epidemiologic reports indicate a
rise in HCV infection among young people throughout the country. Some
jurisdictions have noted that the number of people ages 15 to 29 being
diagnosed with HCV infection now exceeds the number of people diagnosed in all
other age groups combined. Alarmingly, 35 out of 41 responding states reported
increases in persons newly infected with HCV from 2010-2012.

Further, the “baby boomer” population (those born between 1945 through
1965) currently accounts for three out of every four cases of chronic HCV. As
these Americans continue to age, they are likely to develop complications from
HCV and require costly medical interventions that can be avoided if they are
tested earlier and provided with curative treatment options. It is estimated
that this epidemic will increase costs to private insurers and public systems,
such as Medicare and Medicaid, from $30 billion in 2009 to over $85 billion in
2024, and account for additional billions of lost productivity due to the
millions of workers suffering from chronic HBV and HCV. Over the last three
years, CDC and the USPSTF have worked to align their recommendations for hepatitis
screening, recommending screening vulnerable groups for HCV and one-time
testing of all baby boomers.

We appreciate the Committee’s support for viral hepatitis prevention, in
particular the increased support to prioritize the identification of people
living with HBV and HCV who are unaware of their status. We strongly encourage
you to sustain your commitment this year. We have the tools to prevent the
major causes of liver disease and liver cancer – a hepatitis B vaccine and
effective treatments that reduce disease progression, new diagnostics for HCV
and treatments that increase cure rates to over 90%, and even more medical
advances for HBV and HCV in the research pipeline. Making this relatively
modest investment in the prevention and detection of viral hepatitis represents
a key component in addressing a vital public health inequity and will ensure
more Americans receive the appropriate health care, strengthen our public
health infrastructure, and combat the devastating and expensive complications
caused by viral hepatitis.